Is BPC-157 FDA approved? What the FDA records show
The answer to “is BPC-157 FDA approved” is no, based on the FDA records checked October 14, 2026. The 2026 compounding review is a different process: a committee recommendation, prescription, or compounding-list change does not itself approve a finished BPC-157 medicine or establish a specific clinic’s supply route. FDA approval statement; compounding-list rule.
The important question is what someone means by “approved.” Approval of a medicine, rules for a pharmacy ingredient, and a clinic’s promise to supply it need different proof. The record below separates all three.
Is BPC-157 FDA approved? The official status check
FDA’s May 11, 2026 evaluation states that neither BPC-157 free base nor BPC-157 acetate is an ingredient in an approved drug. The other records below answer narrower questions about compounding; none should be read as a blanket approval of BPC-157 or a provider. FDA briefing, page 9.
Compounding means preparing a medicine by combining, mixing, or changing ingredients to meet a patient’s needs. The 503A and 503B names refer to separate federal compounding frameworks. Their bulks lists concern raw active ingredients—not lists of approved finished medicines. FDA’s compounding explanation.
BPC-157 approval and access record
U.S. records checked October 14, 2026. Each finding applies only to its stated requirement. The 503A regulation displayed was current through October 9, 2026; the displayed 503B list page carries an August 21, 2023 update date.
| Requirement or claim | Finding | What was checked and what it establishes | Next question—and what would change the finding |
|---|---|---|---|
| BPC-157 free base or acetate is an ingredient in an FDA-approved medicine. | Contradicted by the FDA evaluation. | The approval statement in the May 11 briefing, page 9, says neither form is a component of an approved drug. | Has FDA since approved a specific product? Request its approval record and approved label. A later product approval would change this finding for that product. |
| An applicable USP or NF drug-substance monograph exists for those forms. | Contradicted in the May evaluation. | FDA reports no applicable official ingredient standard, called a monograph, for either form. Briefing, page 9. This is not an independent October search of USP/NF publications. | Has an applicable standard been published since the evaluation? A new monograph would change this ingredient-standard finding, not create a drug approval. |
| BPC-157 appears on the final 503A bulks list. | Contradicted in the displayed regulation. | The included-substances list in 21 CFR 216.23(a), current through October 9, contains no BPC-157 entry. | Is there a later final rule naming the substance? Read the exact form and effective date before changing this finding. |
| FDA identifies BPC-157 among withdrawn nominations. | Supported. | Its safety-risk page places BPC-157 in the withdrawn-nomination section. Withdrawal does not itself establish approval or permission to supply it. | Has FDA published a new classification or substance-specific action? That record—not the word “withdrawn”—would need review. |
| BPC-157 appears on FDA’s displayed 503B bulks list. | Contradicted in that displayed list. | BPC-157 is absent from the included-substances table, whose page is dated August 21, 2023. This is not a complete assessment of every possible 503B supply basis. | What current 503B record supports the exact ingredient and preparation? A separate applicable action could change the finding. |
| The July advisory review itself provides a finished-drug approval. | Not applicable. | The published questions concern 503A ingredient-list placement. FDA describes the committee’s advice as nonbinding. | Is someone referring to a later final action? Obtain it and check what it actually authorizes. |
| A particular clinic’s advertised BPC-157 offer has an established U.S. dispensing route. | Unresolved. | No individual product, dispensing pharmacy, state-specific offer, or complete supply basis was verified for this page. FDA’s general 503A framework does not settle that transaction. | Ask for the exact product, named pharmacy, current ingredient-specific basis, and state coverage. Review of those records—not an advertisement alone—could resolve the offer. |
How to read the findings: “Supported” supports only the statement beside it. It is not a safety badge. An unresolved supply question does not change the separate answer about drug approval.
If you are checking a clinic offer, the next task is to inspect its access evidence and understand what your payment buys. Use Peptide Care Index's Find My Peptide Path tool to work through the provider and fee questions before paying.
Free to use. No account or email required. The tool provides guided information, not a prescription or a provider match.
What changed for BPC-157 in 2026?
The 2026 records show withdrawn nominations and an FDA compounding advisory review. Those events concern an ingredient-review process; they do not, by themselves, approve a medicine or prove that a clinic can supply it. FDA briefing, pages 8–9; official committee questions.
| Date or record | What the record shows | What it does not establish |
|---|---|---|
| By May 11, 2026: FDA staff evaluation | The nominations had been withdrawn. FDA chose to evaluate both free base and acetate on its own initiative. Briefing, page 8. | An exact withdrawal date, a move into Category 1, or a product approval. |
| May 14, 2026: nomination-category file | The published file has no BPC-157 entry. The safety page checked October 14 identifies it among withdrawn nominations. Category file; withdrawn-nomination entry. | That FDA cleared its safety concerns or added it to a final bulks list. |
| July 23, 2026: advisory question | Separate voting questions asked whether BPC-157 free base and BPC-157 acetate should be placed on the 503A bulks list. Official questions, page 1. | Approval of a finished product. A question sheet also does not establish how the votes were cast. |
| October 14, 2026: regulation check | BPC-157 was absent from the final 503A list in the displayed version, current through October 9. 21 CFR 216.23. | A conclusion about every supply route, or a guarantee that no later document exists elsewhere. |
Does leaving Category 2 mean FDA approval?
No. Category 2 and a withdrawn nomination describe how an ingredient is handled within a compounding-review policy, not whether a finished medicine is approved. Withdrawal is not an automatic move to Category 1. FDA’s category framework.
FDA’s Category 1 policy describes conditions under which the agency does not intend to take certain enforcement action while substances are evaluated. Category 2 concerns nominated substances with identified safety risks that are not covered by that Category 1 policy. Neither label is a consumer product rating.
This explains one source of conflicting online answers. An older description may say “BPC-157 is in Category 2,” while the current FDA page puts it under withdrawn nominations. The current record settles where FDA lists it; it does not settle a pharmacy’s complete basis for supplying it. Current FDA entry.
Did the July review approve BPC-157 for tendon healing?
No. The official review concerned possible 503A list placement, and the use FDA evaluated for BPC-157 was ulcerative colitis, an inflammatory disease of the large intestine. It was not a finished-product approval for tendon healing or every use promoted online. FDA meeting scope.
FDA staff prepare an assessment. Outside advisers give recommendations. FDA then makes its own decisions through the applicable process. A “yes” recommendation on ingredient-list placement would still not be a drug approval.
The practical test for a headline is simple: what was the question, and what official action followed? A report about a vote is not the same document as an effective final rule or an approved product label.
Does “not FDA approved” mean BPC-157 is banned?
Not by itself. “Not FDA approved” answers a product-approval question; it does not resolve every rule about compounding, prescribing, selling, research, or possession. Compounded medicines can meet legitimate patient needs even though the finished compounded products are not FDA-approved. FDA compounding questions and answers.
That does not mean every compounded ingredient or advertised preparation is permitted. For BPC-157, this review has not established a routine, offer-specific U.S. dispensing route. The correct next question is which current rule or policy the named pharmacy relies on for the exact product—not simply whether the clinic accepts appointments.
The displayed 503A regulation does not list BPC-157 in either its included-substances list or its list of substances finally excluded under that rule. Its absence from the included list is therefore not the same as a listed final exclusion, a rejected new-drug application, or a ruling about personal possession. 21 CFR 216.23(a)–(b).
What compounding can—and cannot—establish
Compounding can change a medicine to meet a patient’s needs, such as removing an ingredient the patient cannot tolerate. But an appropriate reason to compound does not remove ingredient requirements, and the resulting preparation is not an FDA-approved generic. FDA’s explanation.
For bulk ingredients under 503A, FDA describes the requirements in this order:
- Follow an applicable USP or NF monograph—an official ingredient standard—if one exists, along with the relevant compounding standards.
- If no applicable monograph exists, use a substance that is a component of an FDA-approved drug.
- If neither applies, the substance must appear on the final 503A bulks list.
FDA also describes a separate interim enforcement policy for certain nominated substances. Its application after BPC-157’s withdrawn nominations remains unresolved in this review. Do not treat an omission from one webpage as proof that the pharmacy qualifies under another rule. FDA’s 503A requirements and interim policy.
503B outsourcing facilities have a different framework. FDA describes a clinical-need bulks list, a separate drug-shortage condition, and an interim policy. A 503A advisory discussion cannot establish a 503B product’s eligibility. Ask a facility citing 503B to identify its actual ingredient-specific basis; this page has not validated one for BPC-157. FDA’s 503B framework.
Is “off-label BPC-157” the same as an approved drug used off label?
No. In FDA’s explanation, off-label use means an unapproved use of an already approved medicine. Calling a BPC-157 offer “off label” does not provide the missing underlying product approval. FDA’s off-label explanation.
For example, an approved medicine used for a different condition still has an underlying product approval. That is different from a prescription for a preparation that has no such approval. A prescription can identify what a clinician intends to prescribe; it is not a substitute for the product record or the pharmacy’s dispensing requirements.
Even with a genuinely approved drug, off-label use does not mean FDA evaluated the benefits and risks for that different use. The product and the claim both matter.
Do capsules, strips, acetate, or other BPC-157 forms change the answer?
A different route or label does not create an FDA approval. The exact ingredient matters too: the July questions named free base and acetate, not every salt, derivative, or blend sold under the BPC-157 name. Official questions; FDA product-approval explanation.
A salt is a particular chemical form of an ingredient. An administration route is how a product enters or is applied to your body. These are separate details to request.
| Name or form on an offer | What the evidence establishes | What you still need to know |
|---|---|---|
| BPC-157 free base or acetate | These are the two forms named in the official committee questions; neither had an approved-drug component basis in FDA’s evaluation. FDA briefing, page 9. | The exact finished product, the claimed status, and any separate compounding basis. |
| BPC-157 arginate or another salt or derivative | The two-form committee questions do not establish the status of another substance. Official scope. | Its exact chemical identity and the primary record that applies to it. Do not assume another name is a permitted workaround. |
| Oral capsules, pills, or tablets | A swallowed form is not automatically an approved medicine. A supplement label is not a drug approval. FDA approval categories. | Whether it is marketed as a drug or supplement, what it actually contains, and what evidence supports that exact product and claim. |
| Sublingual strips, nasal products, topical products, or injections | A route name does not supply an approval record. Results from a different route do not establish the offered preparation’s result. | The exact formulation and evidence for how it is used—not just a study with “BPC-157” in its title. See the original reports below. |
| BPC-157 combined with TB-500 or another peptide | Discussion of one ingredient does not approve the finished combination. | Each exact ingredient, the combined preparation, its supply basis, and evidence for the combination rather than an unrelated single-ingredient study. |
This table is a comparison of what the records can establish, not a recommendation to choose one form. It does not rank absorption, effectiveness, or safety.
What about products labeled “dietary supplement” or “research use only”?
Neither label is an FDA drug approval. FDA does not generally approve dietary supplements before sale, so “not FDA approved” alone also does not settle whether a particular supplement is lawfully marketed. FDA’s explanation of supplement oversight.
“Research use only” is not evidence that a product is suitable for treating a person. In a June 12, 2023 warning letter to Warrior Labz SARMS, FDA addressed human-use marketing for products including BPC-157 despite research-related disclaimers. That is a dated, recipient-specific example—not a new action against every seller. Read the FDA letter.
Do not use a research label as a substitute for a clinical product’s approval or documented access basis. This page does not recommend research-use sellers as treatment suppliers.
Why isn’t BPC-157 approved if human studies exist?
Human BPC-157 reports exist, and some describe improvement. Drug approval still requires a company to submit evidence for a defined product and use, followed by FDA review; publication alone does not create that approval. FDA’s explanation of the approval process.
The small reports below are worth reading accurately. They are not “no evidence,” but they also are not proof that a capsule, strip, injection, or clinic offer will produce the same result for you.
What three original human reports actually found
Selected original reports, checked October 14, 2026—not an exhaustive study register or a treatment comparison. All three concern compounded preparations at private clinics in Florida. The exact BPC-157 salt was not established in the reported methods reviewed here. Results are attributed to the authors, not independently measured by Peptide Care Index.
| Original report | People, route, and study design | What the authors reported, with follow-up | What the report cannot establish |
|---|---|---|---|
| Knee pain — Lee and Padgett, 2021. Original paper. | Retrospective chart review—looking back at prior care. Seventeen treated; 16 reached by phone. Twelve received BPC-157 alone into the knee joint; four received BPC-157 plus thymosin beta-4. | Eleven of the 12 BPC-only patients reported pain improvement. Seven reported improvement lasting six months to one year. Follow-up varied. | No untreated or placebo group; subjective follow-up and varied causes of pain. It does not establish structural healing or benefits from capsules. The combination group is not proof about a specified TB-500 fragment. |
| Bladder pain — Lee, Walker, and Ayadi, 2024. Original paper. | Retrospective report of 12 women with interstitial cystitis, or bladder pain syndrome, after unsuccessful prior treatment. BPC-157 was injected into the bladder wall during an endoscopic procedure—not simply placed as liquid in the bladder. | Ten reported complete symptom resolution; two reported 80% improvement. No adverse events were reported. Follow-up bladder examination was at six weeks; most response questionnaires were at four to six months. | No control or sham-procedure group and a small selected sample. It cannot separate a drug effect from other explanations or establish results from another route. |
| IV safety pilot — Lee and Burgess, 2025. Original paper. | Two adults, both previously exposed to intravenous BPC-157. Observations covered three days, through 24 hours after the second infusion. Neither was being treated for an acute injury. | No side effects were reported. The authors did not identify clinically important adverse changes in the blood markers and vital signs they assessed. | Two previously exposed people and brief observation cannot establish general safety, detect uncommon or delayed harm, or demonstrate injury recovery. |
What those results mean for your decision
A report of improvement is a useful observation, but it does not show what would have happened without the treatment. These small, uncontrolled reports cannot reliably separate a treatment effect from natural recovery, symptom changes over time, expectations, or other care.
That does not prove the reported improvements were unreal. It means they cannot be used to predict your result or to declare a different preparation proven. Likewise, no harm reported in a small, short study is not the same as a product being shown safe for general use.
FDA’s briefing also discusses older human meeting abstracts. The three papers above are a selected review, not a claim that only three human studies exist. Animal experiments, laboratory findings, mechanisms, and personal testimonials must remain separate from human treatment outcomes. FDA’s human-evidence discussion.
What safety uncertainties does FDA identify?
FDA identifies possible immune reactions for certain administration routes, peptide-related impurities, and difficulties establishing the exact active ingredient. Its current entry also describes limited safety information for the proposed routes. FDA’s BPC-157 safety entry.
The technical term immunogenicity means the ability to provoke an immune response. The entry does not provide a reliable rate of harm or show that every person will have a reaction. It does mean that a confident “proven safe” claim goes beyond what that record supports.
These are evidence questions, not a reason to invent a story about why approval has not happened. An FDA staff assessment for compounding is also not a rejection of a finished-drug application. Keep the type of review attached to its conclusion.
How do you check an “FDA-approved BPC-157” claim?
Ask for the exact approved medicine and the FDA record behind the claim. A pharmacy registration, drug code, prescription, or laboratory report answers a different question; none substitutes for a product approval. FDA approval terminology; FDA’s NDC explanation.
- Identify the finished product. Get its full name, active ingredient, form, applicant or manufacturer, and the use being described as approved.
- Request the approval record and label. Ask for the FDA application number and approved labeling for that exact product—not a clinic brochure or ingredient test sheet.
- Check the official record. Drugs@FDA lets you look up approved drugs by product, ingredient, or application number. Match the offered product to the record rather than stopping at a similar name.
- Separate the supply question. If the clinic actually means compounded rather than FDA approved, ask which pharmacy would dispense it and which current rule or policy supports that ingredient and preparation.
You are not expected to become a regulatory lawyer. The point is to get a claim and a supporting record that concern the same thing.
Common claims—and the evidence to request
These are examples of wording to check, not allegations about a named provider. No particular clinic or laboratory certificate was evaluated for this comparison.
| Wording you may see | What it does not prove | A useful question to ask |
|---|---|---|
| “Approved in the July vote” | A committee recommendation is not a finished-drug approval or an effective final rule. | “Are you referring to the advisory vote or a later FDA action? Please send the exact record.” |
| “It came off Category 2” | Withdrawal does not automatically establish Category 1 coverage, final list placement, or this offer’s supply basis. | “Which current rule or policy supports supplying this exact form?” |
| “FDA-registered” or “licensed pharmacy” | Facility or professional status does not approve every product or establish every ingredient requirement. | “Which pharmacy would dispense it, and what is the separate basis for this product?” |
| “It has an NDC number” | An NDC, or National Drug Code, is not FDA approval. FDA expressly warns against that inference. Official explanation. | “What is the product’s approval application number, and where is its approved label?” |
| “99% pure” or “certificate of analysis available” | A purity claim or certificate alone does not establish clinical benefit, sterility, authorization, or suitability for human use. | “Which batch, tests, methods, and limits does the complete report cover? Was sterility actually tested, and what supports the product’s clinical and supply claims?” |
| “Human studies prove it works” | Results from a different product, route, population, or use do not establish the result for this offer. | “Which original study matches the exact preparation, how it is given, and the proposed use?” |
The table applies the official distinctions and the study limits discussed above. A certificate of analysis is a report of tests on a sample. FDA includes a valid certificate among its bulk-ingredient requirements; it is one requirement, not a replacement for all the others. No certificate or batch was tested for this page. FDA’s 503A requirements.
A hypothetical offer, read one claim at a time
An offer can sound reassuring while leaving the important questions unanswered. Here is a hypothetical example—not a real provider, purchase, or conversation:
“FDA-registered pharmacy. BPC-157 reviewed in 2026. Third-party tested. Consultation available.”
Product approval: None of those statements supplies a product-approval record. Registration refers to a facility, review refers to a process, and testing refers to whatever the actual report measured.
Access: Still unresolved. You would need the exact formulation, the dispensing pharmacy, state coverage, and the source supporting that preparation’s supply.
Payment: Also incomplete. A consultation offer does not show the full treatment bill or what happens if nothing can be prescribed or filled.
This does not prove the advertiser is dishonest. It shows which claims still need support. Even confirming one of them would not automatically confirm the others.
Six questions to send before you pay
You can copy these into a message to a clinic you already know. They ask for the missing product, access, and payment details without assuming you need to buy BPC-157.
- What exact peptide, salt or formulation, strength, quantity, and administration route are you offering? Is the finished product compounded?
- Are you claiming FDA product approval? If so, please send the exact approval application and approved label. If you mean registration, committee advice, or compounding status instead, please name that status clearly.
- Which pharmacy would dispense it, and what current source supports supplying this exact product? Please send the relevant rule, policy, or other applicable record.
- Can the clinician and pharmacy serve my state? Who provides care, who takes my payment, and who handles clinical questions or problems afterward?
- What is the complete financial commitment? Please itemize the consultation, product and quantity, mandatory labs, membership, shipping, and follow-up. What is due now, what renews, and which charges are optional?
- What do I owe if no prescription is written or the pharmacy cannot fill it? Which charges are refundable, who issues a refund, and how and when can I cancel future charges?
A listed consultation price is a line on the receipt, not necessarily the full bill. When a required charge is unknown, the total is incomplete—not zero. The fee checklist in Find My Peptide Path walks through those charges without assuming a vial equals a month of treatment.
Already receiving care? Take the exact packaging or product name and these questions to your existing prescriber or pharmacist. This status page is not a personal instruction to start, stop, or change a treatment.
What would change BPC-157’s FDA status?
A verifiable approval for a specific BPC-157 medicine would change the product-approval answer for that product. A final compounding-list action would change a different finding: whether the named ingredient appears on that list. FDA product-approval explanation; 21 CFR 216.23.
The distinction would still matter after a list change. Section 216.23(d) makes clear that a compounded medicine made with an ingredient on that list must not be represented as FDA approved or endorsed. Being added to a compounding list is not a back-door drug approval.
When will BPC-157 be FDA approved?
The records reviewed here do not provide a confirmed finished-drug approval date. A timeline for compounding rulemaking is not a timeline for drug approval, and neither should be presented as inevitable.
Look for the actual product approval and approved label, or the separate final ingredient-list action with its effective date. A proposal, new study, press release, or meeting announcement is not a substitute for the relevant completed action. FDA’s explanation of approval.
Does a clinical-trial listing mean it is approved or available?
No. Research participation and approval for a marketed medicine are separate matters. A listing alone also cannot promise that a study is actively enrolling, that a site is near you, or that you qualify. FDA’s explanation of investigational drugs.
For any study you are considering, read the full current record: who sponsors it, the study status, country and sites, enrollment, eligibility, and last update. Resolve conflicting details with the study team. This page has not verified a recruiting BPC-157 study or a research access route for you.
Does a prescription make BPC-157 allowed in sport?
Do not assume so. For athletes governed by World Anti-Doping Agency rules, the 2026 Prohibited List names BPC-157 under S0 and prohibits it in and out of competition. A compounding headline does not change that published sporting rule. Official 2026 WADA list, page 4.
Check the rules that actually govern your sport and competition year with the relevant anti-doping organization. This is separate from a clinic’s prescribing decision; the rule does not automatically apply to every recreational athlete.
What we actually checked
We reviewed published official records and selected original human reports, then separated what each could establish. This was an editorial source review, not clinical testing, a pharmacy inspection, or a legal assessment of an individual offer.
Peptide Care Index is the independent decision and access index for peptide care—helping you understand the route, the cost, the evidence, and the next step before you pay.
Checked October 14, 2026: FDA’s BPC-157 staff briefing and committee questions; the safety/withdrawal page and nomination-category file; the displayed 503A regulation and 503B list; relevant FDA explanations; the three original reports linked above; and the effective-year WADA entry.
Dates and limits: The FDA evaluation is dated May 11, 2026, and its underlying searches were earlier. The eCFR version displayed was current through October 9, 2026. The 503B list page carries an August 21, 2023 update date. Our check date is not the date those records were created or their underlying research was performed. We did not complete an exhaustive live drug-approval database search or verify the official July vote tally.
Not performed: Provider contact, purchases, clinician or pharmacy license checks, product or batch testing, state-specific coverage verification, or validation of a complete BPC-157 supply route. No named provider fee or offer is endorsed here. AI assisted the research and drafting; no clinician, pharmacist, or regulatory specialist reviewed this work.
Our Peptide Care Access Check method asks: what is required, which evidence applies, what was checked, what does it show, what remains to ask, and what would change the finding? Supported, Contradicted, Unresolved, Conflicting, and Not applicable describe specific requirements—not overall treatment ratings.
Read our editorial standards and funding disclosure. To point out a changed source or an error, use Contact and corrections.
Key records and dates
The links beside individual findings are the supporting sources. These are the main records to inspect when checking whether the status has changed; the original research papers are linked in the study table.
| Record | Source date or version | Where to look |
|---|---|---|
| FDA BPC-157 briefing | Staff evaluation: May 11, 2026 | Pages 8–9: withdrawal, exact forms, review scope, monograph, and approval statement. Staff assessment, not final action. |
| Official July committee questions | July 23–24, 2026 meeting | Page 1: the separate BPC-157 free-base and acetate questions about 503A list placement. |
| 503A regulation | Displayed current through October 9, 2026 | Paragraphs (a) and (b): included and excluded substances; paragraph (d): no claim of FDA approval for resulting compounded products. |
| Nomination-category file and safety-risk entry | Category file: May 14, 2026; safety page checked October 14, 2026 | Distinguish the active categories from the withdrawn-nomination section. |
| Displayed 503B bulks list | Page updated August 21, 2023; checked October 14, 2026 | Included-substances table. A separate 503B framework, not the July 503A question. |
Before you pay, get the missing answers
The FDA-approval question is answered. If you are considering an offer, your remaining task is to inspect what supports supplying that product and what your payment covers.
Find My Peptide Path brings the access summaries, provider checks, fee questions, and questions to copy or print together. Use it with a clinic you already know; you do not need to choose a featured provider.
Free to use. No account or email required. It helps you prepare—not diagnose a condition, approve treatment, or guarantee access.